Long-Term Follow-Up Result of Hydroxyurea Chemotherapy for Recurrent Meningiomas |
Kim, Min-Su
(Department of Neurosurgery, College of Medicine, Yeungnam University)
Yu, Dong-Woo (Department of Neurosurgery, College of Medicine, Yeungnam University) Jung, Young-Jin (Department of Neurosurgery, College of Medicine, Yeungnam University) Kim, Sang Woo (Department of Neurosurgery, College of Medicine, Yeungnam University) Chang, Chul-Hoon (Department of Neurosurgery, College of Medicine, Yeungnam University) Kim, Oh-Lyong (Department of Neurosurgery, College of Medicine, Yeungnam University) |
1 | Stearns B, Losee KA, Bernstein J : Hydroxyurea. A new type of potential antitumor agent. J Med Chem 6 : 201, 1963 DOI |
2 | Stewart BW : Mechanisms of apoptosis : integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86 : 1286-1296, 1994 DOI ScienceOn |
3 | Martin DS, Stolfi RL, Colofiore JR : Perspective : the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest 15 : 372-381, 1997 DOI ScienceOn |
4 | Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE : Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97 : 341-346, 2002 DOI ScienceOn |
5 | Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ : Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 34 : 817-822, 1996 DOI ScienceOn |
6 | Miralbell R, Linggood RM, de la Monte S, Convery K, Munzenrider JE, Mirimanoff RO : The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13 : 157-164, 1992 DOI |
7 | Navarra P, Preziosi P : Hydroxyurea : new insights on an old drug. Crit Rev Oncol Hematol 29 : 249-255, 1999 DOI ScienceOn |
8 | Newton HB : Handbook of brain tumor chemotherapy. Amsterdam, Boston : Elsevier Medical Publishers/Academic Press, 2006, ppxvi, pp510-524 |
9 | Newton HB, Scott SR, Volpi C : Hydroxyurea chemotherapy for meningiomas : enlarged cohort with extended follow-up. Br J Neurosurg 18 : 495-499, 2004 DOI ScienceOn |
10 | Newton HB, Slivka MA, Stevens C : Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49 : 165-170, 2000 DOI ScienceOn |
11 | Newton HB, Turowski RC, Stroup TJ, McCoy LK : Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 33 : 816-832, 1999 DOI ScienceOn |
12 | Noiri E, Masaki I, Fujino K, Tsuchiya M : Efficacy of a continuous syringe extraction method for monitoring hemodialysis ultrafiltrate. ASAIO J 46 : 461-463, 2000 DOI ScienceOn |
13 | Pollock BE, Stafford SL, Utter A, Giannini C, Schreiner SA : Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small- to medium-size meningiomas. Int J Radiat Oncol Biol Phys 55 : 1000-1005, 2003 DOI ScienceOn |
14 | Rohringer M, Sutherland GR, Louw DF, Sima AA : Incidence and clinicopathological features of meningioma. J Neurosurg 71 : 665-672, 1989 DOI |
15 | Rosenthal MA, Ashley DL, Cher L : Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci 9 : 156-158, 2002 DOI ScienceOn |
16 | Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, et al. : Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86 : 845-852, 1997 DOI ScienceOn |
17 | Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. : Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86 : 840-844, 1997 DOI ScienceOn |
18 | Chamberlain MC : Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 84 : 733-736, 1996 DOI ScienceOn |
19 | Simpson D : The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20 : 22-39, 1957 DOI |
20 | Blasberg RG, Patlak C, Fenstermacher JD : Intrathecal chemotherapy : brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195 : 73-83, 1975 |
21 | Chamberlain MC, Glantz MJ : Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113 : 2146-2151, 2008 DOI ScienceOn |
22 | Chamberlain MC, Glantz MJ, Fadul CE : Recurrent meningioma : salvage therapy with long-acting somatostatin analogue. Neurology 69 : 969-973, 2007 DOI ScienceOn |
23 | Chamberlain MC, Johnston SK : Hydroxyurea for recurrent surgery and radiation refractory meningioma : a retrospective case series. J Neurooncol 104 : 765-771, 2011 DOI ScienceOn |
24 | Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL : Benign meningiomas : primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39 : 427-436, 1997 DOI ScienceOn |
25 | Forbes AR, Goldberg ID : Radiation therapy in the treatment of meningioma : the Joint Center for Radiation Therapy experience 1970 to 1982. J Clin Oncol 2 : 1139-1143, 1984 DOI |
26 | Goldsmith BJ, Wara WM, Wilson CB, Larson DA : Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80 : 195-201, 1994 DOI ScienceOn |
27 | Gwilt PR, Tracewell WG : Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 34 : 347-358, 1998 DOI ScienceOn |
28 | Kallio M, Sankila R, Hakulinen T, Jääskeläinen J : Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 31 : 2-12, 1992 DOI |
29 | Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG : Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma : results of a pilot study. J Neurooncol 74 : 157-165, 2005 DOI ScienceOn |
30 | Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, et al. : The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40 : 271-275, 1997 DOI ScienceOn |
31 | Kyritsis AP : Chemotherapy for meningiomas. J Neurooncol 29 : 269-272, 1996 DOI ScienceOn |
32 | Lee JH, Kim OL, Kim SH, Bae JH, Choi BY, Cho SH : Hydroxyurea treatment for unresectable and uecurrent meningiomas. J Korean Neurosurg Soc 30 : S120-S123, 2001 |
33 | Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD : Epidemiology of intracranial meningioma. Cancer 72 : 639-648, 1993 DOI ScienceOn |
34 | Lori F, Lisziewicz J : Hydroxyurea : overview of clinical data and antiretroviral and immunomodulatory effects. Antivir Ther 4 Suppl 3 : 101-108, 1999 |
35 | Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, et al. : Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67 : 221-226, 2004 DOI |
36 | Adegbite AB, Khan MI, Paine KW, Tan LK : The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58 : 51-56, 1983 DOI |